PEGBIO CO-B(02565): The first batch of commercialized prescriptions of Pedacan nationwide has been implemented and the conditions for the second installment of equity payment have been met.

PEGBIO CO-B (02565) announced that as of July 22, 2026, Paidacon has gradually issued the first batch of commercial prescriptions in several medical institutions, including Peking University People's Hospital and Xiangya Second Hospital of Central South University. In the mentioned representative medical institutions, the first prescription at Peking University People's Hospital was issued by Professor Ji Linong, one of the leading experts of Paidacon III clinical research and director of the Endocrinology Department; and the first prescription at Xiangya Second Hospital of Central South University was issued by Professor Zhou Zhiguang, one of the leading experts of Paidacon III clinical research and the head of the National Key Discipline of Metabolism and Endocrinology. The successful landing of the first batch of commercial prescriptions nationwide marks the official entry of Paidacon into the clinical application and patient use stage, and also signifies an important milestone for the first innovative drug independently developed by the group, from independent research and development, clinical research, approval for market launch, to commercial application. Paidacon is a long-acting GLP-1RA weekly formulation independently developed by the group, which has been approved by the China National Medical Products Administration for the treatment of type 2 diabetes in adults. Paidacon is administered once a week at a fixed dose of 0.97mg, with no dose titration required at initiation, and has demonstrated sustained and stable blood sugar control, good safety and gastrointestinal tolerance, as well as multiple metabolic benefits in clinical studies. According to the commercial cooperation agreement between the group and TINR Pharmaceutical, with the successful issuance of the first batch of national commercial prescriptions for Paidacon, the conditions for the payment of the second equity payment specified in the agreement have all been met. TINR Pharmaceutical's obligation to pay the equity payment has officially taken effect. TINR Pharmaceutical has confirmed in writing that the above payment conditions have been met and will pay the second equity payment as stipulated in the commercial cooperation agreement, which is approximately 49 million Hong Kong dollars. The group expects to receive this payment within the payment term specified in the commercial cooperation agreement. The Board believes that the landing of the first batch of national commercial prescriptions for Paidacon is an important milestone for the product to enter the clinical application and patient service stage; the completion of the conditions for the payment of the second equity payment further demonstrates the substantial progress and continuous performance of the commercial cooperation between the group and TINR Pharmaceutical. The above progress marks important advancements for Paidacon in both clinical application and commercial cooperation. The group will continue to closely coordinate with TINR Pharmaceutical to promote market access, academic promotion, channel development, terminal coverage, and patient service for Paidacon in mainland China, and to continue to ensure product quality management and stable supply, further enhancing the clinical and patient accessibility of Paidacon.